Exhibit 99.1

Contact:

Michael Watts
Vice president, investor relations and
corporate communications
858-410-8673

For Immediate Release

Gen-Probe Reports Financial Results for the Fourth Quarter and Full Year 2010

— In Fourth Quarter, Company Generates Record Non-GAAP EPS of $0.61,
17% Higher than in the Prior Year Period, and GAAP EPS of $0.56 —

— For Full Year 2010, Total Revenues of $543.3 Million Grow by 9%,
Non-GAAP EPS of $2.19 Increase by 12% —

SAN DIEGO, CA, February 15, 2011 — Gen-Probe Incorporated (NASDAQ: GPRO) today reported financial results for the fourth quarter and full year 2010, highlighted by record non-GAAP earnings per share (EPS) of $0.61 in the quarter, 17% higher than in the prior year period.

“In the fourth quarter of 2010, Gen-Probe generated record clinical diagnostics sales and an all-time high in earnings per share despite macroeconomic headwinds and unusually strong sales of influenza products a year ago,” said Carl Hull, the Company’s president and chief executive officer. “At the same time, we took important steps to accelerate our future growth by filing US regulatory applications for the APTIMA^® human papillomavirus (HPV) and trichomonas products, and by acquiring GTI Diagnostics.”

Key financial results for the fourth quarter of 2010 were ($ in millions, except EPS):

		Non-GAAP												GAAP
		2010				2009				Change				2010				2009				Change
Product sales		$	131.1			$	135.5				-3	%		$	131.1			$	135.5				-3	%
Total revenues		$	136.7			$	138.9				-2	%		$	136.7			$	138.9				-2	%
Operating profit		$	40.1			$	37.4				+7	%		$	36.8			$	34.9				+5	%
Net income		$	29.4			$	25.8				+14	%		$	27.2			$	24.0				+13	%
EPS		$	0.61			$	0.52				+17	%		$	0.56			$	0.48				+17	%

Key financial results for the full year 2010 were ($ in millions, except EPS):

		Non-GAAP												GAAP
		2010				2009				Change				2010				2009				Change
Product sales		$	522.7			$	483.8				+8	%		$	522.7			$	483.8				+8	%
Total revenues		$	543.3			$	498.3				+9	%		$	543.3			$	498.3				+9	%
Operating profit		$	149.4			$	131.0				+14	%		$	137.8			$	120.1				+15	%
Net income		$	107.5			$	99.8				+8	%		$	106.9			$	91.8				+16	%
EPS		$	2.19			$	1.95				+12	%		$	2.18			$	1.79				+22	%

Revenue Detail

Clinical diagnostics product sales established a new record in the fourth quarter of 2010, with growth driven by the APTIMA Combo 2^® assay for detecting Chlamydia and gonorrhea. Increased APTIMA sales offset lower sales of PRODESSE influenza assays, which were unusually strong in the prior year period due to the H1N1 pandemic. Foreign exchange fluctuations reduced clinical diagnostics sales by an estimated $0.5 million, or less than 1%, compared to the prior year period.

Blood screening product sales decreased in the fourth quarter of 2010, as expected, due to lower sales of TIGRIS^® instruments to Novartis, the Company’s blood screening collaboration partner. Sales of blood screening assays were flat compared to the prior year period. Foreign exchange fluctuations reduced blood screening sales by an estimated $0.7 million, or 1%, compared to the prior year period.

Sales of research products and services in the fourth quarter of 2010 declined mainly due to the divestiture of the BioKits food testing business late in 2009, and foreign exchange effects.

Fourth quarter product sales were ($ in millions):

		Three Months Ended Dec. 31,								Change
		2010				2009				As Reported				Constant Currency
Clinical Diagnostics		$	80.1			$	77.6				+3	%			+4	%
Blood Screening		$	47.6			$	53.4				-11	%			-10	%
Research Products and Services		$	3.4			$	4.4				-23	%			-21	%
Total Product Sales		$	131.1			$	135.5				-3	%			-2	%
Product sales for the full year 2010 were ($ in millions):
		12 Months Ended Dec. 31,								Change
		2010				2009				As Reported				Constant Currency
Clinical Diagnostics		$	305.8			$	274.2				+12	%			+12	%
Blood Screening		$	203.1			$	197.5				+3	%			+3	%
Research Products and Services		$	13.8			$	12.0				+15	%			+17	%
Total Product Sales		$	522.7			$	483.8				+8	%			+8	%

Collaborative research revenues in the fourth quarter of 2010 were $3.7 million, compared to $2.0 million in the prior year period, an increase of 85% that resulted primarily from increased funding from Novartis associated with the development of the fully automated PANTHER™ instrument and the PROCLEIX^® ULTRIO^® Plus assay for the blood screening market.

Royalty and license revenues in the fourth quarter of 2010 were $1.9 million, compared to $1.4 million in the prior year period, an increase of 36% that resulted primarily from higher royalties received from Novartis and Ventana.

GAAP Income Statement Details

Gross margin on product sales was 69.4% in the fourth quarter of 2010, compared to 67.2% in the prior year period. This increase resulted mainly from decreased sales of low-margin instruments.

Acquisition-related amortization expenses were $2.2 million in the fourth quarter of 2010, compared to $1.9 million in the prior year period, an increase of 16% that resulted mainly from the October 2009 acquisition of Prodesse and its related intangible assets.

Research and development (R&D) expenses in the fourth quarter of 2010 were $26.9 million, compared to $27.4 million in the prior year period, a decrease of 2% that resulted primarily from lower clinical trial expenses.

Marketing and sales expenses in the fourth quarter of 2010 were $15.0 million, similar to $15.3 million in the prior year period.

G&A expenses were $15.6 million in the fourth quarter of 2010, compared to $14.9 million in the prior year period, an increase of 5% that resulted mainly from expenses associated with the consolidation of United Kingdom operations and the acquisition of GTI Diagnostics.

Total other income was $1.2 million in the fourth quarter of 2010, compared to $2.3 million in the prior year period. This decrease of 48% resulted primarily from lower realized gains from the sale of marketable securities, lower yields on the Company’s municipal bond portfolio, and lower investment balances due to share repurchases, acquisitions and strategic investments.

Income tax expense was $10.8 million in the fourth quarter of 2010, corresponding to a tax rate of 28%. Income tax expense benefited from the reinstatement of the federal R&D tax credit, which was retroactive to the beginning of 2010.

Non-GAAP Income Statement Details

Excluding $0.1 million of acquisition-related depreciation expense, gross margin on product sales in the fourth quarter of 2010 was 69.5%, compared to 67.3% in the prior year period.

Excluding transaction-related costs, general and administrative (G&A) expenses in the fourth quarter of 2010 were $14.7 million, similar to $14.5 million in the prior year period.

Excluding a $0.4 million non-cash gain on a change in the fair value of contingent consideration, total other income in the fourth quarter of 2010 was $0.8 million, compared to $2.3 million in the prior year period.

Excluding adjustments to contingent consideration that largely are not taxable, income tax expense in the fourth quarter of 2010 was $11.4 million, corresponding to a tax rate of 28%.

Cash Flows and Balance Sheet

In the fourth quarter of 2010, Gen-Probe generated net cash of $43.8 million from operating activities, and spent $8.6 million on property, plant and equipment, leading to free cash flow of $35.2 million. The Company repurchased approximately 245,000 shares of its stock in the fourth quarter for $11.9 million, thereby completing its $100 million buyback program. In a separate press release today, Gen-Probe announced a new, $150 million stock repurchase program.

Gen-Probe continues to have a strong balance sheet. As of December 31, 2010, the Company had $489.7 million of cash, cash equivalents and marketable securities, and $240.0 million of short-term debt. The Company pays interest on this debt at a rate 0.6% above the one-month London Interbank Offered Rate (LIBOR), which has been below 0.3%.

2011 Financial Guidance

“We anticipate 2011 will be a good year financially for Gen-Probe,” said Herm Rosenman, the Company’s senior vice president and chief financial officer. “As we said in our recent analyst day, we forecast continued, high-single-digit growth in product sales, even as instrument sales decline. We also expect improving gross and operating margins to drive solid earnings growth, despite increased legal expenses and lower non-operating income.” Gen-Probe’s 2011 financial guidance is described in the table below:

		Non-GAAP				GAAP
Total revenues			$570 to $595 million				$570 to $595 million
Product gross margins		68% to 69.5%				68% to 69.5%
Acquisition-related amortization and other transaction expense		N/A					$13 to 14 million
Operating margin		27% to 29%				25% to 27%
Tax rate		32% to 33%				32% to 33%
Diluted shares			48 to 49 million				48 to 49 million
EPS			$2.28 to $2.40				$2.06 to $2.20

Notes on Presentation

In this press release, all per share amounts are calculated on a fully diluted basis. Some totals may not foot due to rounding. Certain prior year amounts have been reclassified to conform to the current year presentation.

About Non-GAAP Financial Measures

To supplement Gen-Probe’s financial results for the fourth quarter of 2010 and its 2011 financial guidance, in each case presented in accordance with GAAP, Gen-Probe uses the following financial measures defined as non-GAAP by the SEC: non-GAAP net income, non-GAAP gross margin, non-GAAP marketing and sales expenses, non-GAAP G&A expenses, non-GAAP operating margin, non-GAAP income tax rate, and non-GAAP EPS. Gen-Probe’s management does not, nor does it suggest that investors should, consider such non-GAAP financial measures in isolation from, or as a substitute for, financial information prepared and presented in accordance with GAAP. Gen-Probe’s management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the Company’s performance by excluding certain expenses and adjustments that may not be indicative of core business results. Gen-Probe believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing Gen-Probe’s performance and when planning, forecasting and analyzing future periods. These non-GAAP financial measures also facilitate management’s internal comparisons to Gen-Probe’s historical performance and our competitors’ operating results. Gen-Probe believes these non-GAAP financial measures are useful to investors in allowing for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Further, our reconciliations of non-GAAP to GAAP operating results, which are included on the attached tables, are presented in the format of consolidated statements of income solely to assist a reader in understanding the impact of the various adjustments to our GAAP operating results, individually and in the aggregate, and are not intended to place any undue prominence on our non-GAAP operating results.

Webcast Conference Call

A live webcast of Gen-Probe’s fourth quarter 2010 conference call for investors can be accessed at http://www.gen-probe.com beginning at 4:30 p.m. Eastern Time today. The webcast will be archived for at least 90 days. A telephone replay of the call will be available for approximately 24 hours. Call 800-294-4406 (US) or 203-369-3231 (international).

About Gen-Probe

Gen-Probe is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility. Gen-Probe has approximately 28 years of expertise in nucleic acid testing (NAT), and received the 2004 National Medal of Technology, America’s highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,400 people. For more information, go to www.gen-probe.com.

Trademarks

APTIMA, APTIMA COMBO 2, PANTHER, PRODESSE and TIGRIS are trademarks of Gen-Probe. All other trademarks are the property of their owners.

Caution Regarding Forward-Looking Statements

Any statements in this news release about our expectations, beliefs, plans, objectives, assumptions or future events or performance, including those under the heading “ 2011 Financial Guidance,” are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. For example, statements concerning Gen-Probe’s financial condition, possible or expected results of operations, the development and commercialization of new products, regulatory approvals, future milestones, growth opportunities, and plans of management are all forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied. Some of these risks, uncertainties and assumptions include but are not limited to: (i) the risk that we may not achieve our expected 2011 financial targets, (ii) the risk that we may not integrate acquisitions, such as Tepnel, Prodesse and GTI Diagnostics, successfully, (iii) the possibility that the market for the sale of our new products, such as our PANTHER instrument system and PROGENSA PCA3, APTIMA HPV and APTIMA trichomonas assays, may not develop as expected, (iv) the enhancement of existing products and the development of new products may not proceed as planned, (v) the risk that investigational products, including those now in US clinical trials, may not be approved by regulatory authorities or become commercially available in the time frame we anticipate, or at all, (vi) the risk that we may not be able to compete effectively, (vii) the risk that we may not be able to maintain our current corporate collaborations and enter into new corporate collaborations or customer contracts, (viii) our dependence on Novartis and other third parties for the distribution of some of our products, (ix) our dependence on a small number of customers, contract manufacturers and single source suppliers of raw materials, (x) changes in third-party reimbursement policies regarding our products could adversely affect sales, (xi) changes in government regulation or tax policy affecting our diagnostic products could harm our sales, increase our development costs or increase our taxes, (xii) the risk that our intellectual property may be infringed by third parties or invalidated, and (xiii) our involvement in patent and other intellectual property and commercial litigation could be expensive and could divert management’s attention. This list includes some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we file with the SEC, including our most recent annual report on Form 10-K and all subsequent periodic reports. We assume no obligation and expressly disclaim any duty to update forward-looking statements to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

# # #

Gen-Probe Incorporated

Consolidated Balance Sheets — GAAP
(In thousands, except share and per share data)

		December 31,				December 31,
		2010				2009
		(unaudited)
Assets
Current assets:
Cash and cash equivalents, including restricted cash of $16 and $17 at December 31, 2010 and December 31, 2009, respectively		$	59,690			$	82,616
Marketable securities			170,648				402,990
Trade accounts receivable, net of allowance for doubtful accounts of $355 and $516 at December 31, 2010 and December 31, 2009, respectively			54,739				55,305
Accounts receivable — other			5,493				4,707
Inventories			66,416				61,071
Deferred income tax			13,634				13,959
Prepaid income tax			2,993				7,317
Prepaid expenses			11,672				14,526
Other current assets			5,148				4,708
Total current assets			390,433				647,199
Marketable securities, net of current portion			259,317				15,472
Property, plant and equipment, net			160,863				157,437
Capitalized software, net			13,981				12,560
Patents, net			12,450				1,556
Goodwill			150,308				122,680
Purchased intangibles, net			120,270				108,015
License, manufacturing access fees and other assets, net			60,175				63,266
Total assets		$	1,167,797			$	1,128,185
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable		$	14,614			$	20,455
Accrued salaries and employee benefits			26,825				24,775
Other accrued expenses			13,935				24,755
Income tax payable			634				—
Short-term borrowings			240,000				240,127
Deferred revenue			1,166				3,527
Total current liabilities			297,174				313,639
Non-current income tax payable			8,315				5,958
Deferred income tax			29,775				23,220
Deferred revenue, net of current portion			2,500				1,978
Other long-term liabilities			6,654				16,215
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value per share; 20,000,000 shares authorized, none issued and outstanding			—				—
Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 47,966,156 and 49,143,798 shares issued and outstanding at December 31, 2010 and December 31, 2009, respectively			5				5
Additional paid-in capital			195,820				242,615
Accumulated other comprehensive income			678				4,616
Retained earnings			626,876				519,939
Total stockholders’ equity			823,379				767,175
Total liabilities and stockholders’ equity		$	1,167,797			$	1,128,185

Gen-Probe Incorporated

Consolidated Statements of Income — GAAP
(In thousands, except per share data)
(Unaudited)

		Three Months Ended								Twelve Months Ended
		December 31,								December 31,
		2010				2009				2010				2009
Revenues:
Product sales		$	131,093			$	135,470			$	522,709			$	483,759
Collaborative research revenue			3,708				2,049				14,518				7,911
Royalty and license revenue			1,893				1,351				6,100				6,632
Total revenues			136,694				138,870				543,327				498,302
Operating expenses:
Cost of product sales (excluding acquisition-related intangible amortization)			40,104				44,454				169,222				152,393
Acquisition-related intangible amortization			2,231				1,894				8,847				4,144
Research and development			26,885				27,428				111,103				105,970
Marketing and sales			15,016				15,306				59,492				53,853
General and administrative			15,610				14,925				56,818				61,828
Total operating expenses			99,846				104,007				405,482				378,188
Income from operations			36,848				34,863				137,845				120,114
Other income/(expense):
Investment and interest income			1,401				1,923				11,765				21,603
Interest expense			(535	)			(392	)			(2,216	)			(1,857	)
Gain on contingent consideration			399				—				7,994				—
Other income/(expense), net			(95	)			769				(177	)			(58	)
Total other income, net			1,170				2,300				17,366				19,688
Income before income tax			38,018				37,163				155,211				139,802
Income tax expense			10,780				13,138				48,274				48,019
Net income		$	27,238			$	24,025			$	106,937			$	91,783
Net income per share:
Basic		$	0.57			$	0.49			$	2.20			$	1.82
Diluted		$	0.56			$	0.48			$	2.18			$	1.79
Weighted average shares outstanding:
Basic			47,827				48,923				48,560				50,356
Diluted			48,455				49,458				49,033				50,965

Gen-Probe Incorporated

Consolidated Statements of Income — Non-GAAP Reconciliations
(In thousands, except per share data)
(Unaudited)

		Three Months Ended												Three Months Ended
		December 31, 2010												December 31, 2009
		Non-GAAP				Adjustments				GAAP				Non-GAAP				Adjustments				GAAP
Revenues:
Product sales		$	131,093			$	—			$	131,093			$	135,470			$	—			$	135,470
Collaborative research revenue			3,708				—				3,708				2,049				—				2,049
Royalty and license revenue			1,893				—				1,893				1,351				—				1,351
Total revenues			136,694				—				136,694				138,870				—				138,870
Operating expenses:
Cost of product sales (excluding acquisition-related intangible amortization)			40,013				91				40,104				44,361				93				44,454
Acquisition-related intangible amortization			—				2,231				2,231				—				1,894				1,894
Research and development			26,885				—				26,885				27,428				—				27,428
Marketing and sales			15,016				—				15,016				15,209				97				15,306
General and administrative			14,670				940				15,610				14,479				446				14,925
Total operating expenses			96,584				3,262				99,846				101,477				2,530				104,007
Income from operations			40,110				(3,262	)			36,848				37,393				(2,530	)			34,863
Other income/(expense):
Investment and interest income			1,401				—				1,401				1,923				—				1,923
Interest expense			(535	)			—				(535	)			(392	)			—				(392	)
Gain on contingent consideration			—				399				399				—				—				—
Other income/(expense), net			(95	)			—				(95	)			769				—				769
Total other income, net			771				399				1,170				2,300				—				2,300
Income before income tax			40,881				(2,863	)			38,018				39,693				(2,530	)			37,163
Income tax expense			11,437				(657	)			10,780				13,890				(752	)			13,138
Net income		$	29,444			$	(2,206	)		$	27,238			$	25,803			$	(1,778	)		$	24,025
Net income per share:
Basic		$	0.61			$	(0.04	)		$	0.57			$	0.53			$	(0.04	)		$	0.49
Diluted		$	0.61			$	(0.05	)		$	0.56			$	0.52			$	(0.04	)		$	0.48
Weighted average shares outstanding:
Basic			47,827								47,827				48,923								48,923
Diluted			48,455								48,455				49,458								49,458

Gen-Probe Incorporated

Consolidated Statements of Income — Non-GAAP Reconciliations
(In thousands, except per share data)
(Unaudited)

		Twelve Months Ended												Twelve Months Ended
		December 31, 2010												December 31, 2009
		Non-GAAP				Adjustments				GAAP				Non-GAAP				Adjustments				GAAP
Revenues:
Product sales		$	522,709			$	—			$	522,709			$	483,759			$	—			$	483,759
Collaborative research revenue			14,518				—				14,518				7,911				—				7,911
Royalty and license revenue			6,100				—				6,100				6,632				—				6,632
Total revenues			543,327				—				543,327				498,302				—				498,302
Operating expenses:
Cost of product sales (excluding acquisition-related intangible amortization)			168,860				362				169,222				152,118				275				152,393
Acquisition-related intangible amortization			—				8,847				8,847				—				4,144				4,144
Research and development			111,103				—				111,103				105,970				—				105,970
Marketing and sales			59,492				—				59,492				53,756				97				53,853
General and administrative			54,491				2,327				56,818				55,497				6,331				61,828
Total operating expenses			393,946				11,536				405,482				367,341				10,847				378,188
Income from operations			149,381				(11,536	)			137,845				130,961				(10,847	)			120,114
Other income/(expense):
Investment and interest income			11,765				—				11,765				21,603				—				21,603
Interest expense			(2,216	)			—				(2,216	)			(1,857	)			—				(1,857	)
Gain on contingent consideration			—				7,994				7,994				—				—				—
Other income/(expense), net			(177	)			—				(177	)			(58	)			—				(58	)
Total other income, net			9,372				7,994				17,366				19,688				—				19,688
Income before income tax			158,753				(3,542	)			155,211				150,649				(10,847	)			139,802
Income tax expense			51,303				(3,029	)			48,274				50,825				(2,806	)			48,019
Net income		$	107,450			$	(513	)		$	106,937			$	99,824			$	(8,041	)		$	91,783
Net income per share:
Basic		$	2.21			$	(0.01	)		$	2.20			$	1.98			$	(0.16	)		$	1.82
Diluted		$	2.19			$	(0.01	)		$	2.18			$	1.95			$	(0.16	)		$	1.79
Weighted average shares outstanding:
Basic			48,560								48,560				50,356								50,356
Diluted			49,033								49,033				50,965								50,965

Gen-Probe Incorporated

Consolidated Statements of Cash Flows — GAAP
(In thousands)
(Unaudited)

		Twelve Months Ended
		December 31,
		2010				2009
Operating activities:
Net income		$	106,937			$	91,783
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			44,529				40,382
Amortization of premiums on investments, net of accretion of discounts			9,573				5,868
Stock-based compensation			24,075				23,420
Excess tax benefit from employee stock-based compensation			(3,692	)			(2,005	)
Deferred revenue			(1,808	)			812
Deferred income tax			(3,745	)			(5,786	)
Gain on contingent consideration			(7,994	)			—
Gain on sale of food safety business			—				(291	)
Loss on disposal of property and equipment			1,065				221
Changes in assets and liabilities:
Trade and other accounts receivable			2,649				(11,303	)
Inventories			(1,154	)			2,315
Prepaid expenses			3,055				1,218
Other current assets			(360	)			1,912
Other long-term assets			(559	)			(4,123	)
Accounts payable			(6,265	)			3,500
Accrued salaries and employee benefits			(133	)			(676	)
Other accrued expenses			(4,417	)			(806	)
Income tax payable			7,688				(2,371	)
Other long-term liabilities			122				961
Net cash provided by operating activities			169,566				145,031
Investing activities:
Proceeds from sales and maturities of marketable securities			427,821				438,601
Purchases of marketable securities			(401,434	)			(419,019	)
Proceeds from sale of property, plant and equipment			82				—
Purchases of property, plant and equipment			(30,716	)			(32,364	)
Purchase of capitalized software			(3,891	)			(1,290	)
Purchases of intangible assets, including licenses and manufacturing access fees			(2,513	)			(7,341	)
Net cash paid for business combinations			(53,000	)			(183,725	)
Proceeds from sale of food safety business			—				6,357
Cash paid for investment in Pacific Biosciences			(50,000	)			—
Other			(820	)			403
Net cash used in investing activities			(114,471	)			(198,378	)
Financing activities:
Repurchase and retirement of common stock			(99,935	)			(174,847	)
Proceeds from issuance of common stock and employee stock purchase plan			31,830				10,923
Payment of contingent consideration			(10,000	)			—
Repurchase and retirement of restricted stock for payment of taxes			(1,257	)			(1,716	)
Excess tax benefit from employee stock-based compensation			3,692				2,005
Borrowings, net			(228	)			238,450
Net cash (used in) provided by financing activities			(75,898	)			74,815
Effect of exchange rate changes on cash and cash equivalents			(2,123	)			1,026
Net increase in cash and cash equivalents			(22,926	)			22,494
Cash and cash equivalents at the beginning of period			82,616				60,122
Cash and cash equivalents at the end of period		$	59,690			$	82,616